The size and price range have already been increased for Glaukos (GKOS), a medical technology company that plans to price their IPO on Wednesday. Their device is so small it defies imagination but is a proven treatment for glaucoma.
Three are several reasons the company is experiencing strong demand for their IPO:
- Clinical trials are done and they are in the revenue ramp already. This is a product that is in the early stages of commercial adoption in a large . . .